At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SV2A PET Imaging in Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating UCB-J, MRI Scan, and 1 other intervention for Alzheimer Disease. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The overarching goal of this project is to use \[C-11\]UCB-J to obtain spatial information on neuronal synapse abundance and inform Alzheimer's disease (AD) progression. The investigators propose to collect longitudinal amyloid, tau, and Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) in participants in the Wisconsin Alzheimer's Disease Research Center (ADRC) and Wisconsin Registry for Alzheimer's Prevention (WRAP) across the clinical stages of AD, including cognitively unimpaired biomarker negative, unimpaired biomarker positive, mild cognitive impairment (MCI), and dementia due to AD.
Study Details
Timeline
Arms & Interventions
Participants include both cognitively impaired and unimpaired populations to populate a single model to examine variables within the group as a whole. * Cognitively impaired participants have abnormal cognitive status of MCI or dementia as judged by consensus or expert review using National Institute of Aging and Alzheimer's Association (NIA-AA) 2018 criteria. * Cognitively unimpaired participants: results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
Interventions
PET imaging with UCB-J
MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes
PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer